Corporate News Report – Btcs Inc.
Trading Performance
Btcs (ticker: BTCS) closed 2.7 % higher during the 24‑hour period ending at 11:06 PM Central Europe on Thursday, 22 October 2026.
- Current price: USD 1.10
- Shares outstanding: 52.5 million
- Market capitalization: USD 61.1 million
- Trading volume (last 24 h): USD 1.3 million
- Monthly change: –30.91 % since the previous month‑end
- 200‑day simple moving average: USD 1.58
- 52‑week high: USD 4.34 (27 October 2025)
- 52‑week low: USD 0.96 (17 July 2026)
Recent Corporate Developments
Btcs Inc. announced a partnership with Summit Therapeutics and the ECOG‑ACRIN Cancer Research Group to launch a Phase II/III registration‑enabling trial (EA2251) in advanced biliary tract cancer.
- Trial design: Comparison of ivonescimab plus standard chemotherapy versus established immunotherapy‑plus‑chemotherapy regimens.
- Primary endpoint: Overall survival.
- Site activations (US): Planned for the fourth quarter of 2026.
- Background: The partnership follows a positive interim analysis of a prior Phase III study of ivonescimab, which demonstrated a meaningful survival benefit.
- Broader program: Summit is conducting multiple Phase III investigations of the bispecific antibody across solid‑tumor indications.
Performance of Related Stocks (Last 24 Hours)
| Company | Ticker | % Change | Current Price (USD) | Market Cap (USD) |
|---|---|---|---|---|
| Cardiff Oncology | CRDF | +1.08 % | 0.93 | 73 million |
| Home Federal /La | HFBL | +1.12 % | 22.11 | 71.5 million |
| Skinhealth | SKIN | –1.16 % | 11.1 | 72.6 million |
| Cognition Therapeutics | CGTX | +1.77 % | 0.7 | 71.2 million |
| Range Capital Acquisition | RANG | 0 % | 10.9 | 73 million |
Notable Company Updates
Home Federal /La (HFBL): On 21 October 2026, the company filed a Form 8‑K announcing a quarterly cash dividend of $0.15 per share, payable on 16 November 2026 to shareholders of record as of 2 November 2026. The filing included regulatory disclosures, a press release (exhibit 99.1), and no additional financial statements or material events.
Cognition Therapeutics (CGTX): On 22 October 2026, the company filed a current report stating that the U.S. Food and Drug Administration provided written alignment on key aspects of a Phase III study of its investigational drug zervimesine for dementia with Lewy bodies. The report detailed trial design, patient selection, dosage, duration, endpoints, and included the company’s press release and financial statements. No further operational or financial disclosures were made.
Company Overview – Btcs Inc.
Btcs Inc. is a Nasdaq‑listed online retailer specializing in merchandise related to virtual currencies. The company offers services that include transaction verification, secure information management, digital currency ecosystem oversight, inventory display, and digital wallet management. Further information is available on the company’s website at www.bitcoinshop.us .